Genocea Biosciences Inc. sell StockNews.com
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 18.05.25. The prediction end date can be changed by StockNews_com at any time.Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Genocea Biosciences Inc. | - | - |
iShares Core DAX® | -1.471% | 1.895% |
iShares Nasdaq 100 | -0.486% | 4.395% |
iShares Nikkei 225® | -2.115% | 2.450% |
iShares S&P 500 | 0.394% | 3.118% |
Comments by StockNews_com for this prediction
In the thread Genocea Biosciences Inc. diskutieren